Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Part 1 of Phase 1? Yeah more riddles and questions instead of answers.
Hey, the sell button is right at your mouse's fingertips. Hit it and walk away.
Once again see post 50223...another shareholder who doesn't realize he is about to lose his kids college education fund
Guess you cant call that accumulation
Down 12%....SAY WHAAAAAT?
But, but hes a good boy who is trying to straighten out his life....
Yep, all of this is definitely a move in the right direction. Removal of C1 designation would be huge for the industry. When that happens you want to be in as many pot stocks as possible.
Aside from that I am glad to see GB apply for a patent. They need to keep these applications coming. next run up in the industry will be strong for this stock. They are making some great strides. Summer time might be slow going unless there is some catalyst like reschedule. But, if not, the fall should be good for the industry.
Not much, I was kind of wondering about you also since you didn't post for a while. Good to see you back.
LAS VEGAS, June 25, 2018
LAS VEGAS, June 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) has filed nonprovisional patent applications to protect its myrcene-containing complex mixtures ("MCCC") for the treatment of chronic pain and heart disorders. These new US and PCT international applications claim the benefit of GB Sciences' provisional application previously filed on May 22nd, 2017, supplying additional data from patch-clamp studies on individual cells that further support their claims. Novel pain treatments are a promising field of research and development given concerns regarding opioid usage and potential for abuse. The Company's novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol ("THC"), which minimizes their potential for abuse. Pain represents an estimated health burden of between $560 and 650 billion dollars for chronic pain and between $17 and $20 billion dollars for immunological/neuropathic pain in the US alone. In addition, these novel cardiac formulations address the $316 billion-dollar cardiac therapy market in the US.
"GB Sciences' myrcene-containing complex mixtures for heart disease and chronic pain leverage powerful molecular synergies between specific complex formulations of active ingredients derived from the cannabis plants including many terpenes and minor cannabinoids," said Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc. "Our formulations capture whole plant medicine's benefits, but they are further optimized and standardized. In preclinical studies, these complex mixtures have a greater therapeutic potential than the sums of the therapeutic effects of the individual ingredients. Other companies are creating cannabis-based therapeutics primarily based on one or two major cannabinoids, but our data suggests that complex formulations targeting specific diseases containing as many as a dozen ingredients provide greater potential clinical benefits than single- or double-active ingredient formulas."
The Company's drug discovery efforts were accelerated through the powerful combination of GB Sciences' proprietary in silico prediction approach, termed the GB Sciences' Network Pharmacology Platform ("NPP"), and GB Sciences' proven high-throughput screening techniques using cell-based models of pain and heart disease. The current nonprovisional patent application covers myrcene-containing complex mixtures that are capable of targeting the non-traditional cannabinoid receptor, TRPV1. The latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016.
"GB Sciences is developing these pain and heart formulas in accordance with our strategy of commercializing complex mixtures of cannabis-derived compounds whose pharmaceutical activity does not require THC," explains John Poss, Chairman and CEO of GB Sciences, Inc. "In addition, we are creating time-released forms of these formulations through our joint nanotech research program with the University of Seville. Our commitment to providing novel therapies and improved delivery methods will be tested in a pilot human trial in 2019."
Ok, Pluto chose D.
Why not let it go dark and let the quarterly updates and any PRs drive the conversation?
lets take a poll to answer this question. your choices are:
A. Berman and his minions are too arrogant to give up the argument no matter how fruitless it is.
B. If they stop providing carrots this thing will be sub-penny in a couple more unaudited filings.
C. Bermans gravy train would end
D. Pluto's head would explode because there would be no pressure valve release.
I know, the choices are hard but put down your bets NOW!
LOL, Z, you must not know Dr. Suess and certainly don't understand sarcasm. It was a joke.
"A proof is a proof. What kind of a proof? It's a proof. A proof is a proof. And when you have a good proof, it's because it's proven"
Is this from one of the Dr. Suess Books?
Why don't you post the first part of that 8K, you know, the one posted by the company when they fired Seale and Beers.
Didn't think I really needed to since the letter states that Berman dismissed them and they rebutted his claim as to the reason for the dismissal.
And by the way, they aren't letters.
Lets see...On the Auditors letterhead, in letter format, addressed to DECN, signed by the auditor and included as an exhibit in the filing. Sure looks like a letter. Correspondence then? LOL, whatever floats your boat dude.
Could you post one?
Yes, this is one of my favorites. Berman probably learned to keep his trap shut on subsequent letters so he could have plausible deniability at least.
August 5, 2011
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Dear Sir/Madam:
We have read the statements included under Item 4.01 in the Form 8-K dated August 5, 2011 of InstaCare Corp. (the "Company") to be filed with the Securities and Exchange Commission and we agree with such statements insofar as they relate to our dismissal, except for the Company’s statement that our dismissal was a “result of dissatisfaction with the quality of professional services” rendered by our firm. We cannot confirm the Company’s true reasons for dismissing us, but after analyzing our conduct we have concluded that InstaCare’s dissatisfaction is really misplaced frustration: frustration with both accounting standards and with its inability to prepare financial statements in a timely manner.
We cannot confirm or deny that the appointment of Weaver & Martin LLC was approved by the Board of Directors, or that they were not consulted prior to their appointment as auditors.
Very truly yours,
/s/ Seale and Beers, CPAs
Seale and Beers, CPAs
Las Vegas, Nevada
disassociation letter = the letter that the auditor writes playing nice saying that they have no known issues when the two companies part ways. Guess it should be called a separation letter but we all know this is a legal maneuver so the two parties go their own way without any potential future litigation. Its an easy out for the auditor who at that point had no skin in the game. Berman tried to play each one of these off as the auditors malfeasance. If this happened only one time I wouldn't have thought too much about it but when it happens 3 or 4 times in a row sometimes only lasting a few months you really have to wonder who the problem is...and I am not thinking it was the auditors.
Force connecting random dots is not proof, quoting other posts as if they were the gospel is not proof, and calling these things proof in a message board post doesn't make it so.
Quoting other posts? I quoted my own and yours as part of the conversation to provide context.
Not going to waste my time going back to dig up all those auditing firms and their disassociation letters. I was there, saw it with my own eyes. So, it is fact buddy ol'boy.
DECN cant get audited because their books are not verifiable. Period.
Proof? You have none. This is more of the same supposition I have read for the last 5 years.
Then why haven't they been audited? Proof? you have none. What you have is a string of auditors who all left DECN in the dust when they realized their books were in shambles.
What purpose would a lawsuit serve except perhaps more fodder for the company's detractors.
This whole defense of DECN with this argument is absurd. If it was just paperwork then it would have easily been resolved, especially with a suit. And, in this day and age who cant reproduce the necessary documents needed to get audited. DECN cant get audited because their books are not verifiable. Period. The past auditors dropped them and they cant get anyone else to even look at them.
and just how much information about the litigation has JNJ shared with it's shareholders so far?
well, since the outcome in the one case that was resolved was so immaterial that they haven't had to disclose anything up to this point. DECN has probably had an honorable mention in one paragraph of their filings.
Really?
"Private equity firm Platinum Equity’s US$2.1bn offer to acquire blood glucose monitoring systems maker LifeScan, Inc from US health care products company Johnson & Johnson is backed by US$1.875bn of loans,..."
This article is about the debt portion of the offer. It is more likely that the remainder will be paid by Platinum in cash or some other form. And, since it doesn't address this other portion you assertion that it must be a hold back for litigation is pure speculation on your part or worse.
Unless it is shown that the remainder was an up-front payment offered as good faith to hold the offer until acceptance, it must be assumed that over $200 million has been set aside for things like settlement of litigation.
Since you don't know the specifics of the offer either your statement that "it must be assumed" is without any merit. Simply hogwash.
OWC Pharmaceutical Research Corp. (“OWC”) through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol (“THC”) and cannabidol (“CBD”). The tablet is targeted at different indications and will be available in various ratios of THC to CBD and various doses of these actives.
The tablet will be indicated as a substitute for patients being treated with medical cannabis by smoking. Key indications will include chronic pain syndromes and Fibromyalgia, inter alia. Key advantages of this delivery form over smoking medical cannabis are metered and controlled dosage, fast and effective absorption (disintegration time of the tablet is less than 2 minutes) and ease of use with no hazardous smoke inhalation or adverse environmental effects or issues of passive smoking. The ability to manufacture a tablet under strict quality control and quality assurance standards is intrinsic to this dosage form and to the establishment of strict clinical standards.
OWC has received Institutional Review Board (“IRB”) approval (both national Israeli and Sourasky Medical Center IRBs) and plans to initiate a safety clinical trial in the third quarter of 2018.
I don't paint the tape because I don't even trade this POS stock. I will never again buy anything Berman has anything to do with.
Yep, this is just the next round of gullible shareholders who think they have found the fountain of youth and we all missed it because we got in to early. I will give Berman one thing, he has successfully built a share mill with the paper linings of a visual company. As long as no one ever really audits his financials he can keep this glass house from breaking. IMO, of course.
I don't think you understand the concept of painting the tape.
First, this is a message board meant to share information so why shouldn't he pose such a question....which is more rhetorical I believe.
Second, who wants to ask Berman? The guy writes cryptic press releases/filings, doesn't follow up when promised and fails to execute any semblance of a business plan. How hard would it be to effectively communicate. Seems like he either is writing way above his level to sound more sophisticated than his company is or he is purposefully hiding things. Would not trust him to provide a reliable, honest answer.
Nice day today, GBLX showing a little strength the last couple days.
Zor painted the tape at the end, LOL
It does seem a little incestuous doesn't it?
during 1994 and 1995 the Company improperly recognized revenue from distributors despite the fact that all significant vendor obligations had not been completed and/or collectibility was not probable;
Mugsy, Are you aware that Berman wrote off millions in receivables as bad debt as recently as 2010 or thereabouts. I mean, I can understand having to write off some of your sales/receivables as bad debt or at least make an allowance for it but, geez, Berman pretty much washed all the revenues at the time. One might think that this was some really bad business execution or a way to wash your financials. IMO, of course.
I wasn't referring to the company rationalizing. I was referring to investors rationalizing that what the company was doing was in their best interests.
rationalization is an investors worst nightmare. Its is the penny scams fuel however. DECN is counting on it to cycle through new sets of investors periodically.
actually, it took a dive when you showed up.
no, but I will be your huckleberry
Oooops, there it is 50K to the downside.
Is today a holiday? Not one trade? Berman better get that 10Q out. This stock needs some oxygen otherwise its on life support.
Interesting. Then we could end up with a better deal in the end....Market seems like the current status!
Well, there you go. That deal is off the radar and it sounds like both parties gave it their best effort but couldn't come to terms. Sometimes you just have to walk away from the table and not give away the farm.
Gee. I just cant understand why you were treated with such disdain. I mean, you so pleasant and all....